Carfilzomib: a Tale of a Heartbreaking Moment. Case Report and Concise Review of the Literature.

Carfilzomib: a Tale of a Heartbreaking Moment. Case Report and Concise Review of the Literature. Cardiovasc Hematol Disord Drug Targets. 2018 Dec 04;: Authors: Serra W, Fantin A, Longo C, Rabia G, De Rosa F, Plenteda C, Re F, Crisafulli E, Chetta A Abstract Carfilzomib, a proteasome inhibitor, known as a therapeutical option for people who have already received one or more previous treatments for multiple myeloma, has well known cardiac and systemic adverse effects. There is evidence supporting that adverse effects are dose-dependent, yet there is no known patient phenotype characterized by worse associated consequences, nor are there widely accepted monitoring protocols. In this article we describe two patients with cardiovascular adverse events related to carfilzomib treatment and their clinical course. PMID: 30516116 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research